These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 3018648

  • 21. Cisplatin and etoposide alternating with vincristine, doxorubicin and cyclophosphamide in patients with small cell lung cancer.
    Littlewood TJ, Smith AP, Anderson G, Chappell AG, James KW.
    Eur J Respir Dis; 1985 Oct; 67(4):294-300. PubMed ID: 3000808
    [Abstract] [Full Text] [Related]

  • 22. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 23. Alternating chemotherapy with cyclophosphamide/adriamycin/vincristine (CAV) and cisplatin/etoposide (PVP) against small cell lung cancer. Eastern Shikoku Lung Cancer Chemotherapy Group.
    Bando H, Takishita Y, Ogura T, Sone S, Shimizu E, Nakayama T, Doi H, Kobayashi M.
    Jpn J Clin Oncol; 1991 Dec; 21(6):435-9. PubMed ID: 1666660
    [Abstract] [Full Text] [Related]

  • 24. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
    Johnson DH, Wolff SN, Hainsworth JD, Porter LL, Grosh WW, Hande KR, Greco FA.
    J Clin Oncol; 1985 Feb; 3(2):170-5. PubMed ID: 2981981
    [Abstract] [Full Text] [Related]

  • 25. Single-dose etoposide in combination with vincristine and doxorubicin in the treatment of small-cell lung cancer (SCLC).
    Timothy AR, Calman FM, Bateman NT, Farebrother M, Slevin ML, Bellamy D, Rubens RD, Costello J.
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):45-7. PubMed ID: 2983435
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, Hankins L, Steinberg SM, Edison M, Frame JN, Pass H, Nesbitt J, Holden D, Mulshine JL, Glatstein E, Ihde DC.
    J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
    [Abstract] [Full Text] [Related]

  • 29. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 30. Combination versus alternating chemotherapy in small-cell lung cancer.
    Lai SL, Perng RP.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jul; 63(7):513-20. PubMed ID: 10934803
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
    Shepherd FA, Evans WK, MacCormick R, Feld R, Yau JC.
    Cancer Treat Rep; 1987 Oct; 71(10):941-4. PubMed ID: 2820571
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
    Leighl NB, Goss GD, Lopez PG, Burkes RL, Dancey JE, Rahim YH, Rudinskas LC, Pouliot JF, Rodgers A, Pond GR, Shepherd FA.
    Lung Cancer; 2006 Jun; 52(3):327-32. PubMed ID: 16597474
    [Abstract] [Full Text] [Related]

  • 36. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R, Shin DM, Glisson BS, Fossella FV, Murphy WK, Garden AS, Oswald MJ, Hong WK, Roth JA, Peters LJ.
    Int J Radiat Oncol Biol Phys; 1995 Feb 15; 31(4):807-11. PubMed ID: 7860392
    [Abstract] [Full Text] [Related]

  • 37. Primary chemotherapy of brain metastasis in small-cell lung cancer.
    Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK.
    J Clin Oncol; 1989 Jul 15; 7(7):916-22. PubMed ID: 2544685
    [Abstract] [Full Text] [Related]

  • 38. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
    Johnson DH, Bass D, Einhorn LH, Crawford J, Perez CA, Bartolucci A, Omura GA, Greco FA.
    J Clin Oncol; 1993 Jul 15; 11(7):1223-9. PubMed ID: 8391064
    [Abstract] [Full Text] [Related]

  • 39. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group.
    Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC.
    J Clin Oncol; 1990 Feb 15; 8(2):230-40. PubMed ID: 2153765
    [Abstract] [Full Text] [Related]

  • 40. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun 15; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.